Tolerability and Plasma Drug Level Monitoring of Prolonged Subcutaneous Teicoplanin Treatment for Bone and Joint Infections

ABSTRACT Teicoplanin is a key drug for the treatment of multiresistant staphylococcal bone and joint infections (BJI), yet can only be administered via a parenteral route. The objective of this study was to evaluate the safety and tolerability of subcutaneous (s.c.) teicoplanin for that indication over 42 days. Thirty patients with Gram-positive cocci BJI were included. Once the target of 25 to 40 mg/liter trough serum concentration was achieved, treatment was switched from an intravenous to an s.c. route. No discontinuation of teicoplanin related to injection site reaction and no severe local adverse event were observed. On multivariate analysis, better tolerability was observed at the beginning of treatment, in patients over 70 years old, and for dosages less than 600 mg. In conclusion, we recommend s.c. administration of teicoplanin when needed.

[1]  B. Souweine,et al.  Skin antisepsis with chlorhexidine–alcohol versus povidone iodine–alcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial , 2015, The Lancet.

[2]  P. Kalfon,et al.  Intravascular Complications of Central Venous Catheterization by Insertion Site. , 2015, The New England journal of medicine.

[3]  P. Tourneux,et al.  [Subcutaneous teicoplanin for children with infectious endocarditis]. , 2013, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[4]  Société Française d'Anesthésie et de Réanimation,et al.  [Clinical practice recommendations. Osteoarticular infections on materials (prosthesis, implant, osteosynthesis]. , 2009, Medecine et maladies infectieuses.

[5]  L. Leibovici,et al.  Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis , 2009, Antimicrobial Agents and Chemotherapy.

[6]  B. Debaene,et al.  Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors , 2003, Intensive Care Medicine.

[7]  Wood Mj.  Comparative safety of teicoplanin and vancomycin. , 2000 .

[8]  A. Wilson,et al.  Clinical Pharmacokinetics of Teicoplanin , 2000, Clinical pharmacokinetics.

[9]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[10]  A. Wilson,et al.  Comparative safety of teicoplanin and vancomycin. , 1998, International journal of antimicrobial agents.

[11]  R. Greenberg.  Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin , 1990, Antimicrobial Agents and Chemotherapy.